drugset / Trial / NCT03960151
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy
Timeline
- Start
- 2018-05
- Primary completion
- 2021-05
- Completion
- 2022-03
Outcome
Outcome not reported
Stopped (Business): “Compound was sold by funder and development ceased.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rolapitant | Small molecule | 180 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Olanzapine | Small molecule | 10 mg | Oral |
| Background | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |